Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Irinotecan, Cisplatin and Radiation in Esophageal Cancer
NCT00316862Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Feb 2006
- Primary completion
- Dec 2012
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in esophageal cancer, gastroesophageal junction cancer, sponsored by Cancer and Leukemia Group B. Started Feb 2006; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT00316862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00316862.